Acorn Capital Advisors, LLC reported 19 positions worth $366.46M for the quarter ended Jun 30, 2026, up 41.1% on the prior quarter. It opened 1 new position, added to 5, trimmed 3 and exited 2. Its largest holding is CG Oncology, Inc. at 21.9% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| KPTI Karyopharm Therapeutics Inc. | +1.23M | +427.4% | $12.02M | 4.05% |
| JBIO Jade Biosciences, Inc. | +200.0K | +25.4% | $4.44M | 5.98% |
| AURA Aura Biosciences, Inc. | +333.3K | +56.0% | $2.37M | 1.8% |
| ENGN enGene Therapeutics Inc. | +1.27M | – | $2.20M | 0.6% |
| CGON CG Oncology, Inc. | +999 | +0.1% | $70.98K | 21.94% |
| JSPR Jasper Therapeutics, Inc. | +889 | +1.9% | $11.20K | 0.165% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| ENGN enGene Therapeutics Inc. | +1.27M | $2.20M | 0.6% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | CGON CG Oncology, Inc. | Healthcare | 1.13M | $80.39M | 21.94% | +999 | +0.1% | Added | 1.28% |
| 2 | URGN UroGen Pharma Ltd. | Healthcare | 1.67M | $61.58M | 16.8% | 0 | 0.0% | Unchanged | 3.32% |
| 3 | TRVI Trevi Therapeutics, Inc. | Healthcare | 2.14M | $40.00M | 10.92% | 0 | 0.0% | Unchanged | 1.37% |
| 4 | CADL Candel Therapeutics, Inc. | Healthcare | 3.50M | $36.03M | 9.83% | 0 | 0.0% | Unchanged | 4.6% |
| 5 | PBYI Puma Biotechnology, Inc. | Healthcare | 4.13M | $33.50M | 9.14% | 0 | 0.0% | Unchanged | 8.08% |
| 6 | JBIO Jade Biosciences, Inc. | Healthcare | 986.8K | $21.93M | 5.98% | +200.0K | +25.4% | Added | 1.55% |
| 7 | BCAX Bicara Therapeutics Inc. | Healthcare | 643.4K | $19.10M | 5.21% | -1 | 0.0% | Reduced | 0.95% |
| 8 | KPTI Karyopharm Therapeutics Inc. | Healthcare | 1.52M | $14.83M | 4.05% | +1.23M | +427.4% | Added | 5.25% |
| 9 | OKUR OnKure Therapeutics, Inc. | Healthcare | 2.84M | $12.95M | 3.53% | 0 | 0.0% | Unchanged | 5.69% |
| 10 | HELP Helus Pharma Inc. | Others | 1.54M | $10.18M | 2.78% | 0 | 0.0% | Unchanged | 4.43% |
| 11 | TARA Protara Therapeutics, Inc. | Healthcare | 1.75M | $6.69M | 1.83% | 0 | 0.0% | Unchanged | 2.87% |
| 12 | AURA Aura Biosciences, Inc. | Healthcare | 929.1K | $6.60M | 1.8% | +333.3K | +56.0% | Added | 0.9% |
| 13 | LONA LeonaBio, Inc. | Healthcare | 634.5K | $5.83M | 1.59% | 0 | 0.0% | Unchanged | 2.67% |
| 14 | VSTM Verastem, Inc. | Healthcare | 1.47M | $5.61M | 1.53% | 0 | 0.0% | Unchanged | 1.47% |
| 15 | WHWK Whitehawk Therapeutics, Inc. | Healthcare | 1.14M | $5.22M | 1.42% | 0 | 0.0% | Unchanged | 1.37% |
Tip. Select a row to see that position’s full history at Acorn Capital Advisors.
As of its Q2 2026 13F filing, Acorn Capital Advisors, LLC’s five largest positions were CG Oncology, Inc. (CGON) at 21.9%, UroGen Pharma Ltd. (URGN) at 16.8%, Trevi Therapeutics, Inc. (TRVI) at 10.9%, Candel Therapeutics, Inc. (CADL) at 9.8%, Puma Biotechnology, Inc. (PBYI) at 9.1% of the reported portfolio.
Acorn Capital Advisors, LLC reported a 13F portfolio worth $366.46M across 19 positions for Q2 2026. That is up 41.1% from the previous quarter.
Its largest purchases by value were Karyopharm Therapeutics Inc. ($12.02M), Jade Biosciences, Inc. ($4.44M), Aura Biosciences, Inc. ($2.37M). It opened 1 new positions.
Its largest sales by value were Cardiff Oncology, Inc. ($2.85M), Q32 Bio Inc. ($1.26M), X4 Pharmaceuticals, Inc ($966.58K). It exited 2 positions entirely.
From the Form 13F-HR reports Acorn Capital Advisors, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.